Differences in demographic and clinical characteristics and CAR-T access by race
| . | Caucasian (n = 406) . | AA (n = 34) . | Asian (n = 26) . | P value . |
|---|---|---|---|---|
| Median age, y (range) | 59 (21-84) | 55 (22-74) | 55 (22-80) | .004 |
| Sex (n, %) | ||||
| Male | 251 (62) | 21 (62) | 11 (42) | .14 |
| Female | 155 (38) | 13 (38) | 15 (58) | |
| Histologic subtype,∗ n (%) | ||||
| De novo DLBCL | 279 (77) | 20 (74) | 21 (91) | .25 |
| Transformed FL | 83 (23) | 7 (26) | 2 (9) | |
| DHL/THL, n (%) | ||||
| Yes | 76 (19) | 4 (12) | 3 (12) | .41 |
| No | 330 (81) | 30 (88) | 23 (88) | |
| DEL, n (%) | ||||
| Yes | 68 (21) | 3 (10) | 3 (13) | .27 |
| No | 262 (79) | 27 (90) | 20 (87) | |
| Median number of lines therapy before CAR-T therapy, n (range) | 3 (1-6) | 2.5 (1-5) | 2 (1-6) | .44 |
| CAR-T therapy timing | ||||
| Second line, n (%) | 157 (40) | 10 (30) | 11 (43) | .63 |
| Third line and beyond, n (%) | 172 (46) | 21 (64) | 13 (50) | |
| Autologous SCT before CAR-T therapy, n (%) | ||||
| Yes | 113 (29) | 7 (21) | 2 (8) | .04 |
| No | 274 (71) | 26 (79) | 24 (92) | |
| Median time from diagnosis to CAR-Ts, mo (range) | 18.3 (2.0-440.0) | 20.9 (1.6-255.4) | 13.3 (4.1-91.7) | .45 |
| Median time from last relapse/progression pre–CAR-T CAR-T infusion, mo (range) | 2 (0.0-61.0) | 1.8 (0.3-38.0) | 1.2 (0.3-33.3) | .9 |
| Time from apheresis to CAR-T infusion, mo (range) | 1.1 (0.4-12.7) | 1.1 (0.7-4.9) | 0.9 (0.2-2.2) | .2 |
| Bridging therapy, n (%) | ||||
| Yes | 169 (44) | 20 (61) | 12 (46) | .17 |
| No | 218 (56) | 13 (39) | 14 (54) | |
| Insurance coverage, n (%) | ||||
| Medicare | 183 (45) | 12 (35) | 11 (42) | |
| Medicaid | 23 (6) | 6 (18) | 4 (15) | .09 |
| Private | 192 (47) | 16 (47) | 11 (42) | |
| Self-pay | 7 (2) | 0 (0) | 0 (0) | |
| CAR-T on clinical trial, n (%) | ||||
| Yes | 118 (29) | 5 (15) | 5 (19) | .12 |
| No | 287 (71) | 29 (85) | 21 (81) | |
| CAR-T product (n, %) | ||||
| Axicabtagene-ciloleucel | 255 (63) | 20 (59) | 21 (81) | |
| Tisagenlecleu-cel | 99 (25) | 12 (35) | 4 (15) | .18 |
| Lisocabtagene-maraleucel | 50 (12) | 2 (6) | 1 (4) | |
| IPI at time of CAR-T collection, n (%) | ||||
| 0-3 | 265 (82) | 24 (83) | 18 (78) | .9 |
| 4-5 | 58 (18) | 5 (17) | 5 (22) | |
| LDH elevated at time of CAR-T collection, n (%) | ||||
| Yes | 203 (54) | 13 (41) | 20 (83) | .005 |
| No | 173 (46) | 19 (59) | 4 (17) | |
| Day-180 ORR with CAR-T (%) | 51 | 46 | 19 | .04 |
| Day-180 CR with CAR-T (%) | 43 | 42 | 19 | .15 |
| Further therapy after CAR-T progression, n (%) | ||||
| Yes | 102 (46) | 6 (25) | 5 (28) | .05 |
| No | 118 (54) | 18 (75) | 13 (72) |
| . | Caucasian (n = 406) . | AA (n = 34) . | Asian (n = 26) . | P value . |
|---|---|---|---|---|
| Median age, y (range) | 59 (21-84) | 55 (22-74) | 55 (22-80) | .004 |
| Sex (n, %) | ||||
| Male | 251 (62) | 21 (62) | 11 (42) | .14 |
| Female | 155 (38) | 13 (38) | 15 (58) | |
| Histologic subtype,∗ n (%) | ||||
| De novo DLBCL | 279 (77) | 20 (74) | 21 (91) | .25 |
| Transformed FL | 83 (23) | 7 (26) | 2 (9) | |
| DHL/THL, n (%) | ||||
| Yes | 76 (19) | 4 (12) | 3 (12) | .41 |
| No | 330 (81) | 30 (88) | 23 (88) | |
| DEL, n (%) | ||||
| Yes | 68 (21) | 3 (10) | 3 (13) | .27 |
| No | 262 (79) | 27 (90) | 20 (87) | |
| Median number of lines therapy before CAR-T therapy, n (range) | 3 (1-6) | 2.5 (1-5) | 2 (1-6) | .44 |
| CAR-T therapy timing | ||||
| Second line, n (%) | 157 (40) | 10 (30) | 11 (43) | .63 |
| Third line and beyond, n (%) | 172 (46) | 21 (64) | 13 (50) | |
| Autologous SCT before CAR-T therapy, n (%) | ||||
| Yes | 113 (29) | 7 (21) | 2 (8) | .04 |
| No | 274 (71) | 26 (79) | 24 (92) | |
| Median time from diagnosis to CAR-Ts, mo (range) | 18.3 (2.0-440.0) | 20.9 (1.6-255.4) | 13.3 (4.1-91.7) | .45 |
| Median time from last relapse/progression pre–CAR-T CAR-T infusion, mo (range) | 2 (0.0-61.0) | 1.8 (0.3-38.0) | 1.2 (0.3-33.3) | .9 |
| Time from apheresis to CAR-T infusion, mo (range) | 1.1 (0.4-12.7) | 1.1 (0.7-4.9) | 0.9 (0.2-2.2) | .2 |
| Bridging therapy, n (%) | ||||
| Yes | 169 (44) | 20 (61) | 12 (46) | .17 |
| No | 218 (56) | 13 (39) | 14 (54) | |
| Insurance coverage, n (%) | ||||
| Medicare | 183 (45) | 12 (35) | 11 (42) | |
| Medicaid | 23 (6) | 6 (18) | 4 (15) | .09 |
| Private | 192 (47) | 16 (47) | 11 (42) | |
| Self-pay | 7 (2) | 0 (0) | 0 (0) | |
| CAR-T on clinical trial, n (%) | ||||
| Yes | 118 (29) | 5 (15) | 5 (19) | .12 |
| No | 287 (71) | 29 (85) | 21 (81) | |
| CAR-T product (n, %) | ||||
| Axicabtagene-ciloleucel | 255 (63) | 20 (59) | 21 (81) | |
| Tisagenlecleu-cel | 99 (25) | 12 (35) | 4 (15) | .18 |
| Lisocabtagene-maraleucel | 50 (12) | 2 (6) | 1 (4) | |
| IPI at time of CAR-T collection, n (%) | ||||
| 0-3 | 265 (82) | 24 (83) | 18 (78) | .9 |
| 4-5 | 58 (18) | 5 (17) | 5 (22) | |
| LDH elevated at time of CAR-T collection, n (%) | ||||
| Yes | 203 (54) | 13 (41) | 20 (83) | .005 |
| No | 173 (46) | 19 (59) | 4 (17) | |
| Day-180 ORR with CAR-T (%) | 51 | 46 | 19 | .04 |
| Day-180 CR with CAR-T (%) | 43 | 42 | 19 | .15 |
| Further therapy after CAR-T progression, n (%) | ||||
| Yes | 102 (46) | 6 (25) | 5 (28) | .05 |
| No | 118 (54) | 18 (75) | 13 (72) |
DHL, double-hit lymphoma; DLBCL, diffuse large B-cell lymphoma; IPI, International Prognostic Index; THL, triple-hit lymphoma.
Seventeen patients had other histologies including primary mediastinal large B-cell lymphoma, Richter transformation, and transformed marginal zone lymphoma, and were not included in this analysis.